{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:57:57Z","timestamp":1781715477851,"version":"3.54.5"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Princess Margaret Cancer Centre staff"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phase 1 oncology clinical trials have become increasingly complex, resource-intensive, but essential to modernize drug development. Despite strong academic infrastructure, Canada remains underrepresented in early-phase cancer trials relative to international peers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To advance this vision, this perspective summarizes barriers and opportunities impacting the conduct of phase 1 oncology clinical trials in Canada, based on discussions from sponsor, patient advocate, ethics, and clinical research site representatives across national major phase 1 units at the inaugural \u201cPractical Workshop of Conducting Phase 1 Trials in Canada.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current challenges include overly restrictive and complex trial design that increases participant burden, study activation delays, operational inefficiencies, and limited access to investigational therapies following disease progression. However, Canada\u2019s integrated academic cancer centers, publicly funded healthcare system, and ongoing advances in harmonization strategies present opportunities to strengthen national competitiveness in global site selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Participant-centric strategies, earlier collaboration amongst stakeholders, and targeted operational improvements at local, provincial, and national levels are crucial to elevate Canada as a global leader (CANLead) in phase 1 oncology clinical research. Together, the approaches position Canada to advance its competitiveness and take a more prominent role on the international stage, while also providing a practical framework for developing and optimizing phase 1 units globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag190","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:44:46Z","timestamp":1779363886000},"source":"Crossref","is-referenced-by-count":0,"title":["CAN\n                    <i>L<\/i>\n                    ead: Canada as a Phase 1 Clinical Trial Leader \u2014 Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-7527","authenticated-orcid":false,"given":"Ashley A","family":"Adile","sequence":"first","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Sran","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-2999","authenticated-orcid":false,"given":"Philippe L","family":"Bedard","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-0029","authenticated-orcid":false,"given":"Lindsay","family":"Carlsson","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Doi","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Drummond-Ivars","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials (Solid Tumor) Program, The Ottawa Hospital Research Institute , Ottawa, ON K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevan","family":"Hakgor","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Henderson","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials (Solid Tumor) Program, The Ottawa Hospital Research Institute , Ottawa, ON K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6280-8633","authenticated-orcid":false,"given":"John F","family":"Hilton","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials (Solid Tumor) Program, The Ottawa Hospital Research Institute , Ottawa, ON K1H 8L6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip David","family":"Josephy","sequence":"additional","affiliation":[{"name":"GIST Sarcoma Life Raft Group Canada , Guelph, ON N1G 2G2,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Kremidas","sequence":"additional","affiliation":[{"name":"Association for MultiSite Research Corporations , Lake Mary, FL 32746,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-829X","authenticated-orcid":false,"given":"Jacqueline","family":"Limoges","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Renouf","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, BC Cancer , Vancouver, BC V5Z 4E6,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ross","sequence":"additional","affiliation":[{"name":"Sarcoma Cancer Foundation of Canada , Toronto, ON M4V 1L5,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-0958","authenticated-orcid":false,"given":"Abdulazeez","family":"Salawu","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[{"name":"Oncology Clinical Trials, Research Institute of McGill University Health Centre , Montreal, QC H4A 3J1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0540","authenticated-orcid":false,"given":"Lillian L","family":"Siu","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Voccia","sequence":"additional","affiliation":[{"name":"Clinical Development Operations Canada, Boehringer Ingelheim Canada Ltd , Burlington, ON L7L 5H4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanusya G","family":"Lewis","sequence":"additional","affiliation":[{"name":"Clinical Development Operations Canada, Boehringer Ingelheim Canada Ltd , Burlington, ON L7L 5H4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-3265","authenticated-orcid":false,"given":"Miney","family":"Paquette","sequence":"additional","affiliation":[{"name":"Clinical Development Operations Canada, Boehringer Ingelheim Canada Ltd , Burlington, ON L7L 5H4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7657-9950","authenticated-orcid":false,"given":"Albiruni R Abdul","family":"Razak","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3034-3042","authenticated-orcid":false,"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"University Health Network Drug Development Program (Phase I), Princess Margaret Cancer Centre, ,Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026061711573779300_oyag190-B1","author":"Innovation, Science and Economic Development Canada"},{"key":"2026061711573779300_oyag190-B2","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41416-021-01412-y","article-title":"Randomised phase 1 clinical trials in oncology","volume":"125","author":"Iasonos","year":"2021","journal-title":"Br J Cancer"},{"key":"2026061711573779300_oyag190-B3","doi-asserted-by":"publisher","first-page":"e047557","DOI":"10.1136\/bmjopen-2020-047557","article-title":"Time to market for drugs approved in Canada between 2014 and 2018: an observational study","volume":"11","author":"Lexchin","year":"2021","journal-title":"BMJ Open"},{"key":"2026061711573779300_oyag190-B4","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.9778\/cmajo.20220129","article-title":"Time required to initiate a clinical trial in Canada at the onset of the COVID-19 pandemic: an observational research-in-motion study","volume":"11","author":"Teo","year":"2023","journal-title":"CMAJ Open"},{"key":"2026061711573779300_oyag190-B5","author":"Ormandy"},{"key":"2026061711573779300_oyag190-B6","author":"Korea National Enterprise for Clinical Trials (KoNECT)"},{"key":"2026061711573779300_oyag190-B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.annonc.2022.09.162","article-title":"ESMO Clinical Research Observatory (ECRO). streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials","volume":"34","author":"Perez\u2011Gracia","year":"2023","journal-title":"Ann Oncol"},{"key":"2026061711573779300_oyag190-B8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3325\/cmj.2009.50.111","article-title":"Centralized national ethical review of clinical trials in Croatia","volume":"50","author":"Vitezi\u0107","year":"2009","journal-title":"Croat Med J"},{"key":"2026061711573779300_oyag190-B9","author":"Finnish National Board on Research Integrity (TENK)"},{"key":"2026061711573779300_oyag190-B10","doi-asserted-by":"publisher","first-page":"15562646251332709","DOI":"10.1177\/15562646251332709","article-title":"Fogarty-funded research ethics training programs in Eastern Europe","author":"Anderson","year":"2025","journal-title":"J Empir Res Hum Res Ethics"},{"key":"2026061711573779300_oyag190-B11","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1200\/OP.24.00164","article-title":"North American cancer center clinical research capacity and benchmarking in the postpandemic era","volume":"20","author":"Kasner","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026061711573779300_oyag190-B12","doi-asserted-by":"publisher","first-page":"1570899","DOI":"10.3389\/fphar.2025.1570899","article-title":"Building trust in clinical research: a systems approach to ethical engagement and sustainable outcomes","volume":"16","author":"Blom","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026061711573779300_oyag190-B13","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1200\/JOP.19.00662","article-title":"Barriers to participation in therapeutic clinical trials as perceived by community oncologists","volume":"16","author":"Wong","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026061711573779300_oyag190-B14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-019-1476-5","article-title":"The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence","volume":"18","author":"Naidoo","year":"2020","journal-title":"BMC Med"},{"key":"2026061711573779300_oyag190-B15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41571-023-00853-z","article-title":"Optimizing the FDA\u2019s Project Optimus: opportunities and challenges","volume":"21","author":"Murphy","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061711573779300_oyag190-B16","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-21-1799","article-title":"A grant-based experiment to train clinical investigators: the AACR\/ASCO methods in clinical cancer research workshop","volume":"27","author":"Von Hoff","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026061711573779300_oyag190-B17","doi-asserted-by":"publisher","first-page":"101562","DOI":"10.1016\/j.conctc.2025.101562","article-title":"Evaluating the impact of delayed study startup on accrual in cancer studies","volume":"48","author":"Ratnayake","year":"2025","journal-title":"Contemp Clin Trials Commun"},{"key":"2026061711573779300_oyag190-B18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1557-3265.ADVPRECMED20-26","article-title":"A novel electronic platform to improve clinical trial workflow and screening","volume":"26","author":"Saleh","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026061711573779300_oyag190-B19","author":"Catalis Qu\u00e9bec"},{"key":"2026061711573779300_oyag190-B20"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag190\/68370911\/oyag190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag190\/68370911\/oyag190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag190\/68370911\/oyag190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:57:43Z","timestamp":1781711863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag190\/8690959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag190","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,22]]},"article-number":"oyag190"}}